

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims:**

Claims 1 -21 (Previously cancelled)

Claim 22 (Currently amended): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified ~~anti-angiogenic~~ kringle 5 peptide ~~comprising a~~ wherein said kringle 5 peptide comprises peptide SEQ ID NO:8 corresponding to a region of mammalian plasminogen, and a reactive group coupled ~~thereto,~~ to said kringle 5 peptide said reactive group reacting with an amino group, a hydroxyl group, or a thiol group on a blood component to form a stable covalent bond, wherein said reactive group is selected from the group consisting of succinimidyl and maleimido groups.

Claim 23 (Currently cancelled)

Claim 24 (Previously submitted): The method of claim 22, wherein said blood component is a blood protein.

Claim 25 (Previously submitted): The method of claim 22, wherein said modified peptide is reactive with a thiol group on a blood protein.

Claim 26 (Currently cancelled)

Claim 27 (Currently cancelled)

Claim 28 (Currently amended): A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide comprising a kringle 5 peptide ~~and~~ with a maleimido group coupled thereto, said maleimido group reacting with a thiol group on human serum albumin to form a stable covalent bond wherein said kringle 5 peptide comprises SEQ ID NO:8.

Claim 29 (Currently cancelled)

Claim 30 (Currently cancelled)

Claim 31 (Currently cancelled)

Claim 32 (Currently cancelled)

Claim 33 (Currently amended) A method for providing an anti-angiogenic effect to a patient, comprising administering to the patient a modified kringle 5 peptide of the sequence ~~selected from the group consisting of~~ NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(Nc-MPA)-NH<sub>2</sub> (SEQ ID NO: 31); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 32); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 33); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nc-MPA)-NH<sub>2</sub> (SEQ ID NO: 34); (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 35); (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 36); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nc-MPA)-NH<sub>2</sub> (SEQ ID NO: 37); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO: 38); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO:

~~39); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nc-AEEA-MPA)-NH<sub>2</sub> (SEQ ID NO: 40); and NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nc-AEEA<sub>n</sub>-MPA)-NH<sub>2</sub> (SEQ ID NO: 41).~~

Claim 34 (Currently amended) A method of using a modified kringle 5 peptide ~~comprising a kringle 5 peptide~~ wherein said kringle 5 peptide comprises SEQ ID NO:8 and a maleimido group coupled thereto to said kringle 5 peptide which wherein said maleimido group reacts with a thiol group on a blood protein to form a covalent bond, for manufacturing an anti-angiogenic medicament having an extended *in vivo* half-life compared to said kringle 5 peptide in the absence of said maleimido group.

Claim 35 (Currently amended) A conjugate of formula:

blood component-reactive group-peptide,

wherein said peptide is a kringle 5 peptide comprising SEQ ID NO:8 ~~an anti-angiogenic peptide corresponding to a region of mammalian plasminogen~~, and wherein said reactive group is bonded to an amino group, a hydroxyl group, or a thiol group of said blood component by means of stable covalent bond, said reactive group being selected from the group consisting of succinimidyl and maleimido groups.

Claim 36 (Previously submitted) The conjugate of claim 35, wherein said blood component is a blood protein.

Claim 37 (Currently cancelled)

Claim 38 (Previously submitted): The conjugate of claim 36, wherein said reactive group is covalently bonded to a thiol group on said blood protein.

Claim 39 (Currently cancelled)

Claim 40 (Currently cancelled)

Claim 41 (Previously submitted): The conjugate of claim 36, wherein said blood protein is serum albumin.

Claim 42 (Previously submitted): A composition for providing an antiangiogenic effect to a patient, comprising a conjugate of claim 35 in association with a pharmaceutically acceptable carrier.

Claim 43(Previously submitted): The composition of claim 42, wherein said blood component is a blood protein.

Claim 44 (Currently cancelled)

Claim 45 (Previously submitted): The composition of claim 42, wherein said reactive group is covalently bonded to a thiol group on said blood protein.

Claim 46 (Currently cancelled)

Claim 47 (Currently cancelled)

Claim 48 (Previously submitted): The composition of claim 42, wherein said blood protein is serum albumin.